Distributor contract for UK and Ireland signed with a world leading provider of diagnostic testing and services

DiaGenic announces that it has signed an agreement with a world leading provider of diagnostic testing and services to patients and doctors to market its BCtect® for early detection of breast cancer and ADtect® for early detection of Alzheimer’s in the UK and Ireland. Both tests uniquely use peripheral blood as the sample material to provide early non-invasive diagnosis of these complex diseases. “The agreement is a major milestone in DiaGenic’s development, making these innovative tests commercially available through this prestigious partner in UK and Ireland,” said DiaGenic CEO Erik Christensen, M.D., Ph.D. “Both tests have already attracted major interest amongst clinicians, researchers and patients. Following CE certification in the summer, we are delighted to be able to offer these tests within the UK and Ireland”. A joint press release on product launch will be published at a later stage. Contact person: Erik Christensen, CEO Telephone: + 47 95939918 E-mail: erik.christensen@diagenic.com About DiaGenic ASA DiaGenic is an innovative Norwegian biotechnology company that seeks to create value for patients, partners, and investors by developing new and more patient friendly methods for early detection of diseases. DiaGenic is currently a world leader in analyzing gene expression signatures related to disease in easily available clinical samples such as peripheral blood. This unique method is based on the principle that even when a disease is localized at a specific part of the body, secondary responses, which are also characteristic of the disease, can be measured in other parts. Significant potential in numerous diseases such as breast cancer and Alzheimer's disease has been identified. The company has been granted patents in the U.S. and Europe. DiaGenic is listed on the Oslo Stock Exchange. For more information visit www.diagenic.com